网络Meta分析:比较代偿期MASH肝硬化药物治疗对纤维化逆转和MASH缓解的效果
该系统评价与网络Meta分析检索PubMed和Cochrane Library至2025年5月25日,纳入9项RCT共3266例经活检证实的代偿期MASH肝硬化(F4c)患者,比较药物治疗的组织学疗效。主要终点为纤维化至少逆转1期且MASH不恶化,次要终点为MASH缓解。Efruxifermin是唯一在纤维化改善上显著优于安慰剂的干预,且在MASH缓解上Efruxifermin、semaglutide+cilofexor+firsocostat和semaglutide均显著优于安慰剂。
要点
- Efruxifermin是唯一在纤维化至少逆转1期且MASH不恶化上显著优于安慰剂的药物。
- MASH缓解上,Efruxifermin、semaglutide+cilofexor+firsocostat和semaglutide显著优于安慰剂。
- Efruxifermin在纤维化改善和MASH缓解的SUCRA排名中均居首位。
核心结论
- 该网络Meta分析提供了代偿期MASH肝硬化可用药物治疗组织学疗效的相对排名估计,可能对未来临床试验设计有启示。
研究设计与样本
- 系统评价与网络Meta分析,检索PubMed和Cochrane Library从建库至2025年5月25日。
- 纳入9项随机对照试验,共3266例经活检证实的代偿期MASH肝硬化(F4c)患者。
- 主要终点为纤维化至少逆转1期且MASH不恶化,次要终点为MASH缓解。
- 采用网络Meta分析进行比较,并使用累积排名曲线下面积(SUCRA)估计排名概率。
主要发现
- Efruxifermin是唯一在纤维化至少逆转1期且MASH不恶化上显著优于安慰剂的干预。
- 纤维化改善排名最高的干预为efruxifermin(SUCRA: 77.44)、cilofexor+firsocostat(SUCRA: 72.38)和aldafermin(SUCRA: 71.27)。
- MASH缓解上,efruxifermin、semaglutide+cilofexor+firsocostat和semaglutide显著优于安慰剂。
- MASH缓解排名最高的干预为efruxifermin(SUCRA: 81.38)、semaglutide+cilofexor+firsocostat(SUCRA: 74.07)和semaglutide(SUCRA: 63.88)。
临床怎么用
- 对于代偿期MASH肝硬化(F4c)患者,现有证据中efruxifermin在纤维化逆转和MASH缓解上均显示相对优势。
- semaglutide单药或联合cilofexor+firsocostat在MASH缓解方面显著优于安慰剂。
- 该网络Meta分析的排名数据可为未来临床试验设计提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The burden of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis is rapidly rising globally. There are several therapeutic agents under clinical development for the treatment of cirrhosis due to MASH; however, their relative efficacy has not been systematically assessed. This systematic review and network meta-analysis was performed to compare the histological efficacy of available therapeutic agents for compensated MASH cirrhosis. METHODS: PubMed and Cochrane Library databases were searched from inception to May 25, 2025, for randomised controlled trials (RCTs) evaluating pharmacological treatments in patients with biopsy-proven compensated MASH cirrhosis (F4c). The primary endpoint was fibrosis regression of at least one stage without MASH worsening, and the secondary endpoint was MASH resolution. Treatment comparisons were conducted via network meta-analysis, and ranking probabilities were estimated using the surface under the cumulative ranking (SUCRA) curve analysis. RESULTS: Nine RCTs with 3266 participants met the eligibility criteria. Efruxifermin was the only intervention significantly superior to placebo for ≥ 1-stage fibrosis improvement without worsening of MASH. The highest-ranked interventions for fibrosis improvement were efruxifermin (SUCRA: 77.44), cilofexor + firsocostat (SUCRA: 72.38) and aldafermin (SUCRA: 71.27). For MASH resolution, efruxifermin, semaglutide + cilofexor + firsocostat and semaglutide were significantly superior to placebo. Efruxifermin (SUCRA: 81.38), semaglutide + cilofexor + firsocostat (SUCRA: 74.07) and semaglutide (SUCRA: 63.88) had the highest probability of ranking best for MASH resolution. CONCLUSION: This network meta-analysis provides relative rank-order estimates of the histological efficacy of available pharmacological therapies for compensated MASH cirrhosis. These data may have implications for the design of future clinical trials.
引用
- Souza M, Al-Sharif L, Antunes VLJ, et al. Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution. Aliment Pharmacol Ther. 2026. PMID: 41645601. doi:10.1111/apt.70565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。